Milestone Pharmaceuticals is a Montreal-based late-stage biopharmaceutical company led by President and CEO Joseph Oliveto. Its lead investigational product is etripamil, intended to provide rapid-onset, short-acting treatment of paroxysmal supraventricular tachycardia (PSVT) episodes and other episodic conditions. The company is executing an ongoing Phase 3 clinical program for etripamil. Milestone intends to use recent financing to complete the Phase 3 program, fund select commercial pre-launch activities for etripamil, and expand its pipeline. It plans studies of etripamil in other cardiovascular indications where calcium channel blockers have demonstrated utility. Milestone maintains a U.S. subsidiary in Charlotte, N.C. Milestone Pharmaceuticals is a Montreal-based clinical-stage cardiovascular company advancing etripamil, a novel, potent, short-acting calcium channel blocker formulated as a fast-acting nasal spray for patient-administered termination of PSVT episodes. The company completed a US$55M Series C to fund its next development steps. It intends to use the proceeds to advance etripamil into Phase 3 development, including execution of pivotal and supportive clinical trials and production of clinical and commercial supplies. Milestone will also invest in pre-launch commercialization activities and expand resources, including select additional headcount and advisory support in Marketing and Medical Affairs. Joseph Oliveto serves as President and Chief Executive Officer. The company maintains operations in Montreal, Canada, and has a U.S. subsidiary in Charlotte, NC. Milestone Pharmaceuticals is a Saint-Laurent, Canada–based clinical-stage cardiovascular company developing MSP-2017, a novel short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). MSP-2017 is being developed as a patient self-administered intranasal spray to terminate PSVT at the onset of episodes and is currently in Phase 2 clinical development. The company is led by CEO Philippe Douville. Milestone closed a US$17M Series B financing and intends to use the funding to complete Phase 2 clinical development of MSP-2017. The Series B was led by Domain Associates with participation from existing investors Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In connection with the financing, Domain’s Debra Liebert will join Milestone’s board of directors. Milestone Pharmaceuticals is a Montreal (Quebec), Canada–based company developing cardiovascular therapeutics. Its lead candidate series, MSP-2017 and related products, targets episodic treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT) and stable angina. The company intends to use newly raised funds to continue development of MSP-2017 and related programs. Milestone was founded in 2005 and is led by CEO Philippe Douville. In June 2011 it completed a $13m equity financing to support its development plans. The financing coincided with additions to the company's board of directors.

Total raised

$165M

Funding rounds

4

Latest round

Equity

Latest activity

Oct 2018